Radiovirotherapy: Principles and prospects in oncology

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3313-3320

  Touchefeu, Y ^a,b   Franken, P ^c   Harrington, K J ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Laboratoire TIRO   (France)

Author keywords

Gene therapy; Oncolytic viruses; Radioisotope; Radiotherapy; Sodium iodide symporter

Indexed keywords

ASTATINE 211; CARBON 11; FLUORINE 18; IODINE 124; IODINE 131; ISOTOPE; ONCOLYTIC VIRUS; RHENIUM 186; RHENIUM 188; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M;

AVIADENOVIRUS; BACULOVIRUS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RADIOVIROTHERAPY; CELL DIVISION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DNA DAMAGE; DRUG DELIVERY SYSTEM; EFFUSION; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MEASLES VIRUS; MOLECULAR IMAGING; NONHUMAN; ONCOLYTIC VIROTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOISOTOPE THERAPY; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION;

EID: 84862574587     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023313     Document Type: Review

References (93)

1. Touchefeu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiother Oncol 2011; 99: 262-70.
2. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
3. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther2008; 15: 877-84.
4. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med 2011; 364: 542-50.
5. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
6. Jung H. The sodium/substrate symporter family: structural and functional features. FEBS Lett 2002; 529: 73-7.
7. Massart C, Corbineau E. Transporteurs d'iodures et fonction thyroïdienne. Immuno-analyse & Biologie Spécialisée 2006; 21: 138-143.
8. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13: 797-826.
9. Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart JM. Immunohistochemical analysis of Na+/I-symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol 1999; 141: 382-6.
10. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998; 83: 1746-51.
11. Spitzweg C, Dutton CM, Castro MR, et al. Expression of the sodium iodide symporter in human kidney. Kidney Int 2001; 59: 1013-23.
12. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 2007; 109: 1972-9.
13. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1999; 353: 2111-5.
14. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998; 280: 347-55.
15. Read CH, Jr., Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004; 89: 4229-33.
16. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium lodide symporter. Biochem Biophys Res Commun 1996; 226: 339-45.
17. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-60.
18. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA. A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol2002; 16: 2266-82.
19. Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001; 276: 21458-63.
20. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 2000; 167: 125-35.
21. Boelaert K, Smith VE, Stratford AL, et al. PTTG and PBF repress the human sodium iodide symporter. Oncogene, 2007; 26: 4344-56.
22. Smith VE, Read ML, Turnell AS, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009; 122: 3393-402.
23. Saez C, Martinez-Brocca MA, Castilla C, et al. Prognostic significance of human pituitary tumor-transforming gene immunohistochemical expression in differentiated thyroid cancer. J Clin Endocrinol Metab 2006; 91: 1404-9.
24. Caraccio N, Giannini R, Cuccato S, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 2005; 90: 1156-62.
25. Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weetman AP. Regulation and tissue distribution of the human sodium iodide symporter gene. Clin Endocrinol (Oxf) 1998; 49: 517-23.
26. Spitzweg C, Scholz IV, Bergert ER, et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 2003; 144: 3423-32.
27. Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, et al. Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res Treat 2008; 109: 263-72.
28. Unterholzner S, Willhauck MJ, Cengic N, et al. Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells. J Clin Endocrinol Metab 2006; 91: 69-78.
29. Willhauck MJ, DJ OK, Wunderlich N, Goke B, Spitzweg C. Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of (1)(3) (1)I by carbamazepine in breast cancer cells. Breast Cancer Res Treat 2011; 125: 377-86.
30. Scholz IV, Cengic N, Goke B, Morris JC, Spitzweg C. Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. J Clin Endocrinol Metab 2004; 89: 1108-16.
31. Arturi F, Ferretti E, Presta I, et al. Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line. J Clin Endocrinol Metab 2005; 90: 2321-6.
32. Ryan J, Curran CE, Hennessy E, et al. The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One 2011; 6: e16023.
33. Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 2010; 20: 965-74.
34. Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY, Brent GA. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. J Endocrinol 2008; 199: 243-52.
35. Kogai T, Ohashi E, Jacobs MS, et al. Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways. J Clin Endocrinol Metab 2008; 93: 1884-92.
36. Baril P, Martin-Duque P, Vassaux G. Visualization of gene expression in the live subject using the Na/I symporter as a reporter gene: applications in biotherapy. Br J Pharmacol 2010; 159: 761-71.
37. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Voges J, Jacobs AH. Methods to monitor gene therapy with molecular imaging. Methods 2009; 48: 146-60.
38. Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G. Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum Gene Ther 2002; 13: 1723-35.
39. Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Reader AJ, Vassaux G. Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9: 436-42.
40. Merron A, Peerlinck I, Martin-Duque P, et al. SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther 2007; 14: 1731-8.
41. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography. Mol Imaging Biol 2006; 8: 324-32.
42. Dingli D. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
43. Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. AJR Am J Roentgenol 2010; 195: 341-9.
44. Barton KN, Stricker H, Brown SL, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16: 1761-9.
45. Msaouel P, Opyrchal M, Galanis E. Translational research in oncolytic measles virotherapy: early discoveries and future steps. Future Microbiol 2011; 6: 125-8.
46. Peerlinck I, Merron A, Baril P, et al. Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res 2009; 15: 6595-601.
47. Chen RF, Li ZH, Pan QH, et al. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoterdriven expression of the human sodium-iodide symporter. Pancreatology 2007; 7: 505-13.
48. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors. Hum Gene Ther 2006; 17: 661-8.
49. Faivre J, Clerc J, Gerolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004; 64: 8045-51.
50. Herve J, Cunha AS, Liu B, et al. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther 2008; 19: 915-26.
51. Hakkarainen T, Rajecki M, Sarparanta M, et al. Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter. Clin Cancer Res 2009; 15: 5396-403.
52. Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum Gene Ther 2007; 18: 916-24.
53. Dwyer RM, Bergert ER, O'Connor M K, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483-9.
54. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006; 13: 60-6.
55. Msaouel P, Iankov ID, Allen C, et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17: 2041-8.
56. Goel A, Carlson SK, Classic KL, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007; 110: 2342-2350.
57. Shen DH, Marsee DK, Schaap J, et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 2004; 11: 161-9.
58. Willhauck MJ, Sharif Samani BR, Gildehaus FJ, et al. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression. J Clin Endocrinol Metab 2007; 92: 4451-8.
59. Supiot S, Thillays F, Rio E, et al. [Alpha-radioimmunotherapy: a review of recent developments]. Cancer Radiother 2007; 11: 252-9.
60. Petrich T, Quintanilla-Martinez L, Korkmaz Z, et al. Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporterexpressing tumors. Clin Cancer Res 2006; 12: 1342-8.
61. Willhauck MJ, Samani BR, Wolf I, et al. The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1272-81.
62. Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002; 12: 19-26.
63. Huang M, Batra RK, Kogai T, et al. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 2001; 8: 612-8.
64. Lecat-Guillet N, Ambroise Y. Enhanced iodide sequestration by 3-biphenyl-5,6-dihydroimidazo[2,1-b]thiazole in sodium/iodide symporter (NIS)-expressing cells. ChemMedChem 2008; 3: 1211-6.
65. Lecat-Guillet N, Ambroise Y. Synthesis and evaluation of imidazo[2,1-b]thiazoles as iodide efflux inhibitors in thyrocytes. ChemMedChem 2009; 4: 1819-30.
66. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305.
67. Anderson BD, Nakamura T, Russell SJ, Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004; 64: 4919-26.
68. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008; 68: 4882-92.
69. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog 2011; 7: e1002240.
70. Bossow S, Grossardt C, Temme A, et al. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011; 18: 598-608.
71. Ungerechts G, Springfeld C, Frenzke ME, et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-7.
72. Ungerechts G, Springfeld C, Frenzke ME, et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007; 67: 10939-47.
73. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006; 66: 11840-50.
74. Liu C, Hasegawa K, Russell SJ, Sadelain M, Peng KW. Prostatespecific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 2009; 69: 1128-41.
75. Willmon C, Harrington K, Kottke T, Prestwich R, Melcher A, Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 2009; 17: 1667-76.
76. Power AT, Bell JC. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Ther 2008; 15: 772-9.
77. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007; 15: 114-22.
78. Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009; 15: 7246-55.
79. Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virusinfected cell carriers. Mol Ther 2010; 18: 1155-64.
80. Lamfers ML, Fulci G, Gianni D, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006; 14: 779-88.
81. Hingorani M, White CL, Zaidi S, et al. Radiation-mediated upregulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin Cancer Res 2008; 14: 4915-24.
82. Harrington KJ, Nutting CM. Interactions between ionizing radiation and drugs in head and neck cancer: how can we maximize the therapeutic index? Curr Opin Investig Drugs 2002; 3: 807-11.
83. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-87.
84. Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010; 77: 773-83.
85. Barton KN, Stricker H, Elshaikh MA, et al. Feasibility of Adenovirus-Mediated hNIS Gene Transfer and (131)I Radioiodine Therapy as a Definitive Treatment for Localized Prostate Cancer. Mol Ther 2011.
86. Hingorani M, White CL, Merron A, et al. Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer Res 2008; 68: 9771-8.
87. Hingorani M, White CL, Zaidi S, et al. Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol Ther 2010; 18: 1599-605.
88. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-63.
89. McCart JA, Mehta N, Scollard D, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther 2004; 10: 553-61.
90. Akinlolu O, Ottolino-Perry K, McCart JA, Reilly RM. Antiproliferative effects of 111Inor 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor. Cancer Biother Radiopharm 2010; 25: 325-33.
91. Jia ZY, Deng HF, Huang R, et al. In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma. Cancer Gene Ther 2011; 18: 196-205.
92. Brader P, Kelly KJ, Chen N, et al. Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene. Clin Cancer Res 2009; 15: 3791-801.
93. Quigg M, Mairs RJ, Brown SM, et al. Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. Med Chem 2005; 1: 423-9.